Gold: Narrowing Range, Cautiously Bullish

Spot gold has been trading within a narrowing range in the last few weeks, ahead of the upcoming Fed FOMC meeting...

Gold 4

Spot gold has been trading within a narrowing range in the last few weeks, after volatile trading in early August. Pharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine AZD1222 have resumed in the UK, following confirmation by the Medicines Health Regulatory Authority that it was safe to do so.

While gold prices have been dragged by vaccine development, investors continue to expect the Federal Reserve, which will hold a two-day monetary policy meeting mid-week, to keep its dovish stance.

From a technical point of view, spot gold maintains a bullish bias as shown on a daily chart. It is trading within a symmetrical triangle pattern, while support is provided by the ascending 50-day moving average. The level at $1,900 might be considered as the nearest support, with the 1st and 2nd resistance likely to be located at $2,015 and $2,075 respectively. Alternatively, a break below $1,900 would suggest that a deeper price correction is due and open a path to the next support at $1,865.

Source: Gain Capital, TradingView

More from Gold


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.